Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Other Accumulated Expenses: 2010-2024

Historic Other Accumulated Expenses for China Pharma Holdings (CPHI) over the last 7 years, with Dec 2024 value amounting to $1.6 million.

  • China Pharma Holdings' Other Accumulated Expenses rose 6614.61% to $1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 million, marking a year-over-year increase of 6614.61%. This contributed to the annual value of $1.6 million for FY2024, which is 26.44% up from last year.
  • According to the latest figures from FY2024, China Pharma Holdings' Other Accumulated Expenses is $1.6 million, which was up 26.44% from $1.3 million recorded in FY2023.
  • In the past 5 years, China Pharma Holdings' Other Accumulated Expenses registered a high of $2.8 million during FY2021, and its lowest value of $1.3 million during FY2023.
  • For the 3-year period, China Pharma Holdings' Other Accumulated Expenses averaged around $1.8 million, with its median value being $1.6 million (2024).
  • Its Other Accumulated Expenses has fluctuated over the past 5 years, first spiked by 30.23% in 2021, then slumped by 49.29% in 2023.
  • Over the past 5 years, China Pharma Holdings' Other Accumulated Expenses (Yearly) stood at $2.1 million in 2020, then soared by 30.23% to $2.8 million in 2021, then decreased by 10.93% to $2.5 million in 2022, then slumped by 49.29% to $1.3 million in 2023, then climbed by 26.44% to $1.6 million in 2024.